Man Group plc Has $418.85 Million Stock Holdings in Boston Scientific Corporation $BSX

Man Group plc grew its position in Boston Scientific Corporation (NYSE:BSX) by 14.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,392,725 shares of the medical equipment provider’s stock after purchasing an additional 548,788 shares during the period. Boston Scientific comprises about 0.7% of Man Group plc’s portfolio, making the stock its 12th largest position. Man Group plc’s holdings in Boston Scientific were worth $418,846,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of BSX. Brighton Jones LLC raised its holdings in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares during the period. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the second quarter worth $26,000. Main Street Financial Solutions LLC raised its holdings in shares of Boston Scientific by 35.3% during the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after acquiring an additional 1,971 shares during the period. Ieq Capital LLC raised its holdings in shares of Boston Scientific by 97.0% during the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after acquiring an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC raised its holdings in shares of Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after acquiring an additional 2,556 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Down 4.4%

Shares of BSX stock opened at $44.86 on Thursday. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 1 year low of $44.79 and a 1 year high of $109.50. The firm’s fifty day moving average price is $55.38 and its two-hundred day moving average price is $73.62. The firm has a market capitalization of $66.68 billion, a P/E ratio of 18.77, a PEG ratio of 0.90 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period in the previous year, the business earned $0.75 EPS. The company’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of the stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig purchased 3,580 shares of the stock in a transaction on Wednesday, May 20th. The stock was acquired at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 9,800 shares of company stock worth $554,012. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BSX. Wolfe Research lowered shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Daiwa Securities Group lowered shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Piper Sandler restated an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Weiss Ratings lowered shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Finally, Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $85.08.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.